Investigational drug · Phase 3
LHRH Agonist
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
418
Any phase or sponsor naming "LHRH Agonist"
First trial start
2020
Oct 9, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LHRH Agonist", any sponsor or status.
Conditions studied
As listed on its trial records.
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Early Breast Cancer
- Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Breast Cancer
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "LHRH Agonist" as an intervention, largest first.
IVFarma LLCIndustry
NCT04854707 · 5,484 participants · Start Jan 12, 2020 · Primary completion Dec 20, 2020
Drug: Follitropin Alfa; Follicle Stimulating Hormone/Luteinizing Hormone and 3 more · For: Reproductive Issues; Reproductive Disorder; Fertility Disorders and 3 more
Sites: Barnaul, Russia; Irkutsk, Russia; Kazan', Russia · 35 sites in all
Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
NCT03778359 · 5,000 participants · Start Jan 1, 2005 · Primary completion Dec 31, 2015
Drug: Leuprorelin; Dienogest and 1 more · For: Endometriosis; Adenomyosis
Sites: Taipei County, Taiwan
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
NRG OncologyAcademic, hospital or other
NCT05879926 · 3,960 participants (planned) · Start Oct 18, 2023 · Primary completion Jan 2032
Drug: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,276 sites in all
- Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate CancerPivotal-lookingActive, not recruiting
Radiation Therapy Oncology GroupResearch network
NCT01368588 · 2,590 participants · Start Jul 2011 · Primary completion Apr 17, 2025
Drug: Anti-androgen; luteinizing hormone-releasing hormone (LHRH) agonist or antagonist · For: Prostate Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 478 sites in all
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03767244 · 2,517 participants · Start Jun 11, 2019 · Primary completion Dec 1, 2026
Drug: Apalutamide; Androgen Deprivation Therapy (ADT) and 1 more · For: Prostatic Neoplasms
Sites: La Jolla, California; Los Angeles, California; Orange, California · 203 sites in all
Organon and CoIndustry
NCT00724789 · 2,066 participants · Start Nov 2000 · Primary completion Nov 2005
Drug: ganirelix; GnRH agonist · For: Pregnancy; Neonates
- Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate CancerPivotal-lookingStatus unknown
Radiation Therapy Oncology GroupResearch network
NCT00567580 · 1,792 participants · Start Feb 2008 · Primary completion Jul 12, 2018
Drug: AA; LHRH agonist · For: Prostate Cancer
Sites: Birmingham, Alabama; Fairbanks, Alaska; Peoria, Arizona · 460 sites in all
- Intermittent Androgen Deprivation Therapy in the Era of AR Pathway InhibitorsPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT05974774 · 1,600 participants (planned) · Start May 23, 2025 · Primary completion May 23, 2035
Drug: iMAB; cMAB · For: Prostate Cancer
Sites: Copenhagen, Denmark; Caen, France; Grenoble, France · 9 sites in all
- Hormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00005044 · 1,579 participants · Start Feb 2000 · Primary completion Sep 2012
Drug: Casodex; Eulexin and 1 more · For: Prostate Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 261 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Leuprorelin Acetate for Spinal and Bulbar Muscular Atrophy: A Systematic Review of Clinical Efficacy, Long-Term Outcomes, and Safety Considerations.
Wang B, Wang I, Park C, et al. · Muscle Nerve 2026
- H&E to recurrence score: A step forward, but not yet a substitute for genomic testing.
Zhou S, Ke Q · Transl Oncol 2026
- Meningioma enlargement associated with luteinizing hormone-releasing hormone agonist therapy: two cases and supporting in vitro evidence.
Ichinose T, Kinoshita M, Sakaguchi M, et al. · Brain Tumor Pathol 2026
- French multicentre randomised phase III trial evaluating the efficacy and safety of vaginal radiofrequency in the management of vulvovaginal atrophy and dryness in patients treated for breast cancer (RF-Vaginale): trial protocol.
Demetz J, Vanseymortier M, Martin C, et al. · BMJ Open 2026
- Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.
Seyyar M, Şanc PC, Doğan A, et al. · BMC Cancer 2026
- Luteinizing hormone-releasing hormone in prostate cancer treatment: from hypothalamic discovery to clinical translation.
Benisti S, Saad F, Delouya G, et al. · JNCI Cancer Spectr 2026
Also in development for Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.